Business Description
Mustang Bio Inc
NAICS : 325414
SIC : 2836
ISIN : US62818Q2030
Description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.59 | |||||
| Equity-to-Asset | -1.2 | |||||
| Debt-to-Equity | -0.11 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 28.8 | |||||
| 3-Year EPS without NRI Growth Rate | 30.1 | |||||
| 3-Year FCF Growth Rate | 21.5 | |||||
| 3-Year Book Growth Rate | -91.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | |||||
| Quick Ratio | 0.4 | |||||
| Cash Ratio | 0.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.4 | |||||
| Shareholder Yield % | 168.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -170.64 | |||||
| ROIC % | -335.75 | |||||
| ROC (Joel Greenblatt) % | -755.58 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.28 | |||||
| EV-to-Forward-EBIT | -0.43 | |||||
| EV-to-EBITDA | -0.29 | |||||
| EV-to-Forward-EBITDA | -0.43 | |||||
| EV-to-FCF | -0.39 | |||||
| Earnings Yield (Greenblatt) % | -357.14 | |||||
| FCF Yield % | -183.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mustang Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.435 | ||
| Beta | 1.61 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 4.89 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 4.89 - 4.89 | ||
| Shares Outstanding (Mil) | 47.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mustang Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mustang Bio Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mustang Bio Inc Frequently Asked Questions
What is Mustang Bio Inc(STU:2W60)'s stock price today?
The current price of STU:2W60 is €4.89. The 52 week high of STU:2W60 is €4.89 and 52 week low is €4.89.
When is next earnings date of Mustang Bio Inc(STU:2W60)?
The next earnings date of Mustang Bio Inc(STU:2W60) is 2025-03-11 Est..
Does Mustang Bio Inc(STU:2W60) pay dividends? If so, how much?
Mustang Bio Inc(STU:2W60) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers